Hologic, Inc. (NASDAQ:HOLX) Given Average Recommendation of “Hold” by Analysts

Hologic, Inc. (NASDAQ:HOLXGet Rating) has received a consensus recommendation of “Hold” from the eleven ratings firms that are covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $76.71.

A number of analysts have recently weighed in on the company. Morgan Stanley cut their target price on Hologic from $72.00 to $70.00 and set an “equal weight” rating for the company in a research report on Thursday, July 28th. Bank of America downgraded Hologic from a “buy” rating to a “neutral” rating and cut their target price for the company from $81.00 to $75.00 in a research report on Wednesday, July 20th. UBS Group assumed coverage on Hologic in a research report on Wednesday, July 20th. They set a “neutral” rating and a $73.00 target price for the company. Finally, BTIG Research downgraded Hologic from a “buy” rating to a “neutral” rating in a research report on Monday, July 18th.

Hologic Stock Performance

HOLX opened at $66.82 on Monday. The business has a fifty day simple moving average of $70.09 and a 200 day simple moving average of $72.51. The company has a market capitalization of $16.68 billion, a PE ratio of 11.27, a price-to-earnings-growth ratio of 0.76 and a beta of 1.05. Hologic has a 1 year low of $66.36 and a 1 year high of $80.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.91 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLXGet Rating) last released its quarterly earnings results on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.26. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $896.71 million. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The firm’s quarterly revenue was down 14.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.33 EPS. Research analysts expect that Hologic will post 5.82 EPS for the current year.

Institutional Investors Weigh In On Hologic

Several hedge funds have recently added to or reduced their stakes in the business. Fieldpoint Private Securities LLC lifted its position in shares of Hologic by 61.4% in the 1st quarter. Fieldpoint Private Securities LLC now owns 334 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 127 shares during the period. Hudock Inc. lifted its position in shares of Hologic by 1,825.0% in the 1st quarter. Hudock Inc. now owns 385 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 365 shares during the period. Heritage Financial Services LLC acquired a new position in shares of Hologic in the 2nd quarter worth approximately $27,000. Glassman Wealth Services lifted its position in shares of Hologic by 59.6% in the 2nd quarter. Glassman Wealth Services now owns 415 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 155 shares during the period. Finally, Clear Street Markets LLC lifted its position in shares of Hologic by 409.8% in the 2nd quarter. Clear Street Markets LLC now owns 520 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 418 shares during the period. 85.70% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

(Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

See Also

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.